ERCC1 mRNA Levels and Survival in Advanced Gastric Cancer
Author Information
Author(s): Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez J J, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, Liu B
Primary Institution: Department of Oncology, Drum Tower Hospital, Clinical Cancer Institute of Nanjing University, Medical School of Nanjing University, Nanjing, China
Hypothesis
Molecular markers involved in DNA repair can help to predict survival in gastric cancer patients treated with 5-FU plus platinum chemotherapy.
Conclusion
Patients with low ERCC1 mRNA levels have significantly longer survival compared to those with high levels.
Supporting Evidence
- Median survival time for patients with low ERCC1 expression levels was 15.8 months compared to 6.2 months for those with high levels.
- Patients with high TS levels had longer survival than those with low levels (12.2 vs 10.1 months).
- Forty-eight patients with low ERCC1 and high TS levels had a median survival of 16.1 months.
Takeaway
This study found that patients with lower levels of a specific gene (ERCC1) lived longer after treatment for stomach cancer.
Methodology
Real-time quantitative PCR was used to assess ERCC1 and TS mRNA expression levels in tumor samples from patients treated with a modified FOLFOX regimen.
Participant Demographics
Median age was 57; 56 patients were male; majority had performance status 0-1.
Statistical Information
P-Value
P<0.0001
Confidence Interval
95% CI: 10.2–21.5 months for low ERCC1; 95% CI: 4.6–7.9 months for high ERCC1.
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website